| Characteristic | Details |
|---|---|
| Active Ingredients | Sildenafil 100 mg, Duloxetine 30 mg |
| Dosage Forms | Tablets |
| Administration Route | Oral |
| Prescription Required | Yes |
| Indications | Erectile Dysfunction, Premature Ejaculation |
| Visit Official Site | |
Pharmacokinetics
Malegra DXT combines Sildenafil 100 mg and Duloxetine 30 mg. These components exhibit distinct pharmacokinetic profiles. Sildenafil has a high absorption rate with a peak plasma concentration reached within 30 to 120 minutes post-oral administration. It undergoes hepatic metabolism primarily via CYP3A4 and, to a lesser extent, CYP2C9. Its half-life spans around 3 to 5 hours.
Duloxetine, absorbed more gradually, reaches its peak concentration in 6 hours. The bioavailability stands at approximately 50%. It undergoes extensive liver metabolism involving CYP1A2 and CYP2D6 isoenzymes. Its elimination half-life averages 12 hours. These combined properties ensure rapid onset and sustained efficacy for Malegra DXT.
Mechanism of Action
Sildenafil 100 mg in Malegra DXT functions as a phosphodiesterase type 5 (PDE5) inhibitor. It facilitates erection by enhancing blood flow to the penis in the presence of sexual stimulation. This is achieved through the relaxation of smooth muscle in the corpus cavernosum.
Duloxetine 30 mg, a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), contributes to delaying ejaculation. It modulates neurotransmitter levels, boosting serotonin and norepinephrine activity in the central nervous system. This action supports the treatment of premature ejaculation by improving ejaculatory control.
Malegra DXT Precautions
Before using Malegra DXT, consider specific precautions. Patients with cardiovascular conditions should exercise caution due to potential hemodynamic changes. Liver impairment could alter the metabolism of Sildenafil and Duloxetine, necessitating dose adjustments or alternative treatments.
Renal function assessments are advisable, given the drug’s excretory pathways. Malegra DXT may interact with nitrates, leading to significant hypotension. Combining with potent CYP3A4 inhibitors can heighten Sildenafil’s concentration, risking adverse effects.
Pregnancy and Breastfeeding
Malegra DXT is not intended for use in females, especially during pregnancy or breastfeeding. Its components lack safety data in pregnant or lactating women. The potential for fetal harm or transmission through breast milk remains undocumented.
Healthcare providers should emphasize the contraindication of Malegra DXT in these populations. Male patients with partners who are pregnant or nursing should seek medical guidance to avoid inadvertent exposure.
Malegra DXT Signs and Symptoms of Overdose
Overdose symptoms may include severe hypotension, dizziness, and prolonged erections. Nausea and vomiting could manifest due to excessive Duloxetine levels. Monitor for respiratory distress and cardiovascular instability.
Seek immediate medical intervention in suspected overdose cases. Symptomatic and supportive treatment should be prioritized to mitigate risks associated with Malegra DXT excess.
Purchasing Malegra DXT Without a Prescription
Purchasing Malegra DXT without a prescription is highly discouraged. Self-medication risks outweigh benefits due to potential contraindications and interactions. Prescribing ensures appropriate dosage, monitoring, and management of side effects.
Engaging with licensed pharmacies guarantees the authenticity of Malegra DXT. Counterfeit products prevalent online pose significant health risks. Consulting healthcare professionals before procurement upholds treatment safety and efficacy.